Suven Life Sciences Ltd (SUVEN)
₹375.30
Mkt cap
₹10,657 Cr
P/E ratio
—
P/B
16.75
Div yield
0.00%
ROE
−81.50%
ROCE
−79.50%
EPS (TTM)
—
Book value
₹22
52W range
127–392
Sector
Healthcare
Price history
Previous close
Suven Life Sciences is a clinical-stage biopharmaceutical company developing proprietary New Chemical Entities for central nervous system disorders. Its five clinical assets target agitation in Alzheimer’s dementia, narcolepsy, major depressive disorder and cognitive disorders. [1] [2]
NSE SUVENBSE 530239
Health check
Cautious
ProfitabilityWeak
GrowthLow
TechnicalsBullish
52-week range
−4.27% from high₹375
₹127+196.33% from low₹392
Current
₹375.30
Prev close
₹377.20
Day
−0.50%
Price performance
1D
−0.50%
1W
−1.65%
1M
+12.84%
3M
+39.62%
6M
+174.78%
1Y
+71.95%
YTD
+127.72%
Financials
Revenue, profit & margin
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4 | 3 | 2 | 2 | 1 | 3 | 2 | 1 | 2 | 1 | 3 | 2 | 4 | |
| Expenses | 32 | 27 | 49 | 33 | 32 | 55 | 41 | 45 | 53 | 81 | 106 | 52 | 136 | |
| Operating Profit | -28 | -24 | -46 | -30 | -31 | -52 | -39 | -44 | -51 | -80 | -103 | -51 | -132 | |
| OPM % | -737% | -768% | -1,885% | -1,267% | -3,024% | -2,032% | -2,435% | -2,981% | -2,714% | -8,671% | -3,678% | -3,331% | -3,711% | |
| Other Income | 6 | 13 | 6 | 4 | 4 | 4 | 2 | 1 | 1 | 4 | 3 | 7 | 8 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | |
| Profit before tax | -24 | -13 | -42 | -28 | -28 | -50 | -39 | -44 | -52 | -77 | -102 | -46 | -128 | |
| Tax % | 0% | 0% | 0% | -4% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | |
| Net Profit | -24 | -13 | -42 | -27 | -28 | -50 | -39 | -44 | -52 | -77 | -102 | -46 | -128 | |
| EPS in Rs | -1.10 | -0.58 | -1.91 | -1.22 | -1.29 | -2.28 | -1.79 | -2.01 | -2.36 | -3.40 | -4.48 | -1.73 | -4.83 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −2.68% · closed higher next day 0 of last 1
| Q1FY27† | |
|---|---|
| Broadcast | 6 Aug '26 |
| Earnings day | −2.68% |
| +1 day | −2.50% |
| +5 days | −0.03% |
| +15 days | +12.72% |
| +30 days | — |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jul 202665.47%Promoter
Promoters65.47%4.61
FIIs0.48%0.08
DIIs2.73%0.20
Public31.32%4.90
Ownership trend
Peers
7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SYNGENE | ₹389.30 | 53.06 | 15,715 | 0.32% | −9 | −94.89% | 736 | −15.84% | 9.99% |
| INDGN | ₹599.35 | 34.69 | 14,440 | 0.38% | 116 | −0.17% | 1,063 | +39.73% | 18.82% |
| SUVEN | ₹377.15 | — | 10,657 | 0.00% | −128 | −147.69% | 4 | +90.91% | −79.54% |
| VIMTALABS | ₹640.65 | 35.43 | 2,863 | 0.31% | 21 | +11.38% | 109 | +11.80% | 25.23% |
| FABTECH | ₹148.47 | 13.57 | 660 | 0.40% | 4 | +154.79% | 75 | +10.25% | 13.58% |
| BI | ₹100.64 | 11.91 | 237 | 0.00% | 15 | +473.06% | 226 | +21.20% | 5.56% |
| NOVELIX | ₹77.49 | 60.94 | 221 | 0.00% | 1 | +972.73% | 37 | +65.15% | 9.98% |
| Median: 9 Co. | ₹148.47 | 35.91 | 660 | 0.00% | 1 | +117.42% | 75 | +30.46% | 9.99% |
Filings
Annual reports15
Annual Report 2026bseAnnual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2014bseAnnual Report 2013nseAnnual Report 2013bse
Concall transcripts35
PPTJul 2021TranscriptFeb 2020TranscriptNov 2019PPTNov 2019TranscriptAug 2019PPTAug 2019TranscriptMay 2019PPTMay 2019PPTMay 2019TranscriptFeb 2019PPTFeb 2019PPTFeb 2019PPTFeb 2019TranscriptNov 2018PPTNov 2018PPTNov 2018TranscriptAug 2018PPTAug 2018TranscriptMay 2018PPTMay 2018PPTJan 2018PPTDec 2017TranscriptNov 2017PPTNov 2017
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Press Release / Media Release 3 Sep - Suven completed Phase-3 Masupirdine enrollment; 424 patients randomized, topline results expected by May 2027.Shareholder Meeting / Postal Ballot-Outcome of AGM 25 AugShareholder Meeting / Postal Ballot-Scrutinizer''s Report 25 AugAnnouncement under Regulation 30 (LODR)-Monitoring Agency Report 11 Aug - Monitoring agency report for Q1 FY27; no deviations in Rs 85,764.02 lakh preferential issue utilization.Announcement under Regulation 30 (LODR)-Newspaper Publication 7 Aug